Overview
Sepracor's drug development program, together with our corporate development and licensing activities, have yielded a pipeline of pharmaceutical products and candidates that are focused on the treatment of respiratory and central nervous system disorders. We currently market six U.S. Food and Drug Administration (FDA)-approved drugs and have a robust pharmaceutical pipeline that includes candidates directed toward the treatment of depression, epilepsy, pain, asthma, allergic rhinitis and chronic obstructive pulmonary disease. We are committed to the welfare of the patients we serve, and continually seek ways to improve the lives of the millions of people suffering from these potentially debilitating conditions.